McKinsey-grade competitive intelligence for pharma and biotech leadership — at the velocity that modern decision cycles demand.
Market dynamics, pipeline threats, and the next phase of competition in obesity & Type 2 diabetes.
Most pharma intelligence outputs are written either by management consultants who don’t read mechanism-of-action data, or by scientists who don’t price franchise economics. Avenbuan Bio Intelligence sits at the intersection.
Every engagement is sourced to primary documents, framed for boardroom decision-making, and refreshable as new data lands.
McKinsey-grade competitive intelligence on a therapeutic area, pipeline cohort, or specific franchise — refreshed quarterly or on-event.
See deliverableIndependent commercial & clinical evaluation of in-licensing, M&A, and partnership targets. Designed for IC vote.
See deliverablePhase 1 through Phase 3 monitoring with AI-assisted clinical-trial database integration. Real-time alerts on read-outs.
See deliverableEU/UK/US payer, regulatory, and HTA scenario design for novel-mechanism assets — with stress-tested launch economics.
See deliverableSingle-thread strategic memos prepared for principals. Decision-grade language, two-page format, source index attached.
See deliverableCustom analytic engagements for corporate-development, BD&L, and investor-relations teams. Scoped, fixed-fee, two-week sprints.
See deliverableOur debut Competitive Landscape Brief — “The GLP-1 Revolution” — sets the standard for client engagements. 28 pages, every figure sourced, model-ready scenarios.
Market dynamics, pipeline threats, and the next phase of competition in obesity and Type 2 diabetes. Sources: SEC filings, FDA/EMA, NICE, NEJM, IDA Ireland.
Lilly Kinsale and Limerick now produce tirzepatide; Novo Nordisk’s €432m Athlone expansion is the second-largest non-US GLP-1 capacity bet of 2026.
From Amgen MariTide to Viking VK2735 — probability-adjusted threat scoring against the duopoly. Pfizer has left the field.
Send the question. We’ll come back within one working day with scope, timeline, and a fixed fee.